For primary hyperlipidemia. ANDA 209038, held by Alkem Labs Ltd. Colesevelam Hydrochloride.
As of Nov 15, 2026, ANDA 209038 (Colesevelam Hydrochloride), held by Alkem Labs Ltd, was first approved by FDA on Oct 5, 2018, with 3 approved supplements and 0 published complete response letters.
Colesevelam hydrochloride is a bile acid sequestrant indicated as an adjunct to diet and exercise to:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 5, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Colesevelam Hydrochloride625MG · tablet;oral | Colesevelam Hydrochloride | Rx |
| Oct 4, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 4, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 4, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 5, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters